Skip to main content
SpringerLink
Log in

Systematic Review Results on BCG Refractory Disease Management

  • Chapter
  • First Online:
Management of Non-Muscle Invasive Bladder Cancer

  • 502 Accesses

Abstract

A systematic review relating to management in BCG refractory disease was conducted. The search strategy aimed to identify all references related to bladder cancer AND BCG refractory disease. This chapter covers systematic review results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized phase III trial on gemcitabine versus mytomicin in recurrent NMI bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2010;28(4):543–8.

    Google Scholar 

  • Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int. 2009a;104(8):1098–102.

    Article  CAS  Google Scholar 

  • Barlow LJ, McKiernan JM, Benson MC. The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol. 2009b;27(3):331–5.

    Article  CAS  Google Scholar 

  • Bassi PF, Volpe A, D’Agostino D, Palermo G, Renier D, Franchini S, Rosato A, Racioppi M. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol. 2011;185(2):445–9.

    Article  CAS  Google Scholar 

  • Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, Crucitta E, Marini L, Dal Moro F. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. Urol Int. 2005;75(4):309–13.

    Article  CAS  Google Scholar 

  • Belldegrun AS, Franklin JR, O’Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD. NMI bladder cancer: the role of interferon-alpha. J Urol. 1998;159(6):1793–801.

    Google Scholar 

  • Breyer BN, Whitson JM, Carroll PR, Konety BR. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol Oncol. 2010;28(5):510–4.

    Article  CAS  Google Scholar 

  • Dalbagni G, Benfante N, Sjoberg DD, Bochner BH, Machele Donat S, Herr HW, Mc Coy AS, Fahrner AJ, Retinger C, Rosenberg JE, Bajorin DF. Single arm phase I/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus Calmette Guerin (NCT01259063). Bladder Cancer. 2017;3(2):113–119.

    Article  Google Scholar 

  • Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24(18):2729–34.

    Article  CAS  Google Scholar 

  • Gacci M, Bartoletti R, Cai T, Nerozzi S, Pinzi N, Repetti F, Viggiani F, Ghezzi P, Nesi G, Carini M; TUR (Toscana Urologia) Group. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int. 2006;76(2):106–11.

    Article  CAS  Google Scholar 

  • Gallagher BL, Joudi FN, Maymí JL, O’Donnell MA. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology. 2008;71(2):297–301.

    Article  Google Scholar 

  • Gunelli R, Bercovich E, Nanni O, Ballardini M, Frassineti GL, Giovannini N, Fiori M, Pasquini E, Ulivi P, Pappagallo GL, Silvestrini R, Zoli W. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer. 2007;97(11):1499–504.

    Article  CAS  Google Scholar 

  • Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009;27(5):496–501.

    Article  CAS  Google Scholar 

  • Karakiewicz PI, Benayoun S, Lewinshtein DJ, Chun FK, Shahrour K, Perrotte P. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience. Can J Urol. 2006;13(4):3189–94.

    Google Scholar 

  • Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, MacDonald GC. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients. Drug Des Devel Ther. 2010;4:313–20.

    Google Scholar 

  • Luciani LG, Neulander E, Murphy WM, Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory NMI bladder cancer: an investigational approach. Urology. 2001;58(3):376–9.

    Article  CAS  Google Scholar 

  • McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186(2):448–51.

    Article  CAS  Google Scholar 

  • Mohanty NK, Nayak RL, Vasudeva P, Arora RP. Intravesicle gemcitabine in management of BCG refractory NMI TCC of urinary bladder-our experience. Urol Oncol. 2008;26(6):616–9.

    Google Scholar 

  • Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat AM. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol. 2015;193(4):1135–43.

    Article  CAS  Google Scholar 

  • O’Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with NMI bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001;166(4):1300–4, discussion 1304–5.

    Google Scholar 

  • Patel S, Dinh T, Noah-Vanhoucke J, Rengarajan B, Mayo K, Clark PE, Kamat AM, Lee CT, Sexton WJ, Steinberg GD. Novel simulation model of non-muscle invasive bladder cancer: a platform for a virtual randomized trial of conservative therapy vs. Cystectomy in BCG refractory patients. Bladder Cancer. 2015;1(2):143–150.

    Article  Google Scholar 

  • Perdonà S, Di Lorenzo G, Cantiello F, Damiano R, De Sio M, Masala D, Bruni G, Gallo L, Federico P, Quattrone C, Pizzuti M, Autorino R. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21(1):101–6.

    Article  Google Scholar 

  • Rao MV, Quek ML, Jayram G, Ellimoottil C, Sondej T, Hugen CM, Flanigan RC, Steinberg GD. Radical cystectomy after bcg immunotherapy for high-risk nonmuscle-invasive bladder cancer in patients with previous prostate radiotherapy. ISRN Urol. 2013;2013:405064.

    Article  Google Scholar 

  • Robins DJ, Sui W, Matulay JT, Ghandour R, Anderson CB, DeCastro GJ, McKiernan JM. Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus calmette-guérin therapy. Urology. 2017;103:149–153.

    Article  Google Scholar 

  • Rosevear HM, Lightfoot AJ, Birusingh KK, Maymí JL, Nepple KG, O’Donnell MA; National BCG/Interferon Investigator Group. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ. J Urol. 2011;186(3):817–23.

    Google Scholar 

  • Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol. 2017;35(30):3410–3416.

    Article  CAS  Google Scholar 

  • Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–7.

    Article  CAS  Google Scholar 

  • Steinberg GD, Smith ND, Ryder K, Strangman NM, Slater SJ. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ. Postgrad Med. 2011;123(3):28–34.

    Article  Google Scholar 

  • Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. J Urol. 2013;190(5):1686–91.

    Article  CAS  Google Scholar 

  • Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory NMI bladder cancer. J Urol. 2001;165(6 Pt 1):1904–7.

    Google Scholar 

  • Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy. J Urol. 2011;186(5):2094–100.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. East of England Deanery, Norfolk and Norwich University Hospital, Norwich, UK

    Sanchia S. Goonewardene

  2. North Bristol NHS Trust, Bristol, UK

    Raj Persad

  3. Southend University Hospital, Westcliff-on-Sea, UK

    Hanif Motiwala

  4. Boston University, Boston, MA, USA

    David Albala

Authors
  1. Sanchia S. Goonewardene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raj Persad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanif Motiwala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Albala
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanchia S. Goonewardene .

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Goonewardene, S.S., Persad, R., Motiwala, H., Albala, D. (2020). Systematic Review Results on BCG Refractory Disease Management. In: Management of Non-Muscle Invasive Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28646-0_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-28646-0_47

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-28645-3

  • Online ISBN: 978-3-030-28646-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation